Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Conference News EAS 2017

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Yael L. Maxwell

April 25, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Shelley Wood

February 28, 2017

Advertisement

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Statins and Diabetes: Causal Link Reinforced in New Analysis

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content